𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

✍ Scribed by Neerja Bhatla; Vanita Suri; Partha Basu; Surendra Shastri; Sanjoy K. Datta; Dan Bi; Dominique J. Descamps; Hans L. Bock; the Indian HPV Vaccine Study Group

Book ID
109007235
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
977 KB
Volume
36
Category
Article
ISSN
1341-8076

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, immunogenicity, and efficacy of
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Long-term persistence of systemic and mu
Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women
✍ Tiina Petäjä; Court Pedersen; Airi Poder; Gitte Strauss; Gregory Catteau; Floren 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 610 KB

## Abstract Vaccination against oncogenic human papillomavirus (HPV) types is one key intervention for cervical cancer prevention. This follow‐up study assessed the persistence of the systemic and mucosal immune responses together with the safety profile of the HPV‐16/18 AS04‐adjuvanted vaccine adm